Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

NCT07071090 is registered in ClinicalTrials.gov with Heronova Pharmaceuticals as lead sponsor.

NCT NCT07071090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07071090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Lead sponsor
Heronova Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
June 30, 2025
Completion date
January 1, 2028
Enrollment
32 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor malignancies